Adela Periago Peralta

Vasco-Mogorrón MA, Campillo JA, Periago A, Cabañas V, Berenguer M, García-Garay MC, Gimeno L, Soto-Ramírez MF, Martínez-Hernández MD, Muro M, Minguela A. Proliferation to Apoptosis Tumor Cell Ratio as a Biomarker to Improve Clinical Management of Pre-Malignant and Symptomatic Plasma Cell Neoplasms. Int J Mol Sci. 2021 Apr 9;22(8). pii: 3895. doi: 10.3390/ijms22083895. PubMed PMID: 33918790; PubMed Central PMCID: PMC8068942.

AÑO: 2021; IF: 6.208

33918790

Vasco-Mogorrón MA, Campillo JA, Periago A, Cabañas V, Berenguer M, García-Garay MC, Gimeno L, Soto-Ramírez MF, Martínez-Hernández MD, Muro M, Minguela A. Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management. Am J Cancer Res. 2021 Jun 15;11(6):2736-2753. eCollection 2021. PubMed PMID: 34249425; PubMed Central PMCID: PMC8263680.

AÑO: 2021; IF: 5.942

34249425

Minguela A, Salido EJ, Soto-Ramírez MF, Olga MA, Leal JD, García-Garay MC, Periago A, Berenguer M, Blanque M, Campillo JA. Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB, CD16B) deficiency in patients with blood and immune system disorders. Br J Haematol. 2021 Dec;195(5):743-747. doi: 10.1111/bjh.17828. Epub 2021 Sep 20. PubMed PMID: 34544201.

AÑO: 2021; IF: 8.615

34544201

Minguela A, Vasco-Mogorrón MA, Campillo JA, Cabañas V, Remigia MJ, Berenguer M, García-Garay MC, Blanquer M, Cava C, Galian JA, Gimeno L, Soto-Ramírez MF, Martínez-Hernández MD, de la Rubia J, Teruel AI, Muro M, Periago A. Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment. Am J Cancer Res. 2021 Sep 15;11(9):4438-4454. eCollection 2021. PubMed PMID: 34659897; PubMed Central PMCID: PMC8493371.

AÑO: 2021; IF: 5.942

34659897

Martínez-Sánchez MV, Periago A, Legaz I, Gimeno L, Mrowiec A, Montes-Barqueros NR, Campillo JA, Bolarin JM, Bernardo MV, López-Álvarez MR, González C, García-Garay MC, Muro M, Cabañas-Perianes V, Fuster JL, García-Alonso AM, Moraleda JM, Álvarez-Lopez MR, Minguela A. Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology. 2015 Oct 29;5(4):e1093721. eCollection 2016 Apr. PubMed PMID: 27141379; PubMed Central PMCID: PMC4839374.

AÑO: 2016; IF: 7.719

27141379